Rinri Therapeutics awarded $1m Grand Prize at Life Sciences Innovation Summit in Riyadh, Saudi Arabia
Rinri Therapeutics awarded $1m Grand Prize at Life Sciences Innovation Summit in Riyadh, Saudi Arabia
Event led by J.P. Morgan AM & King Abdullah International Medical Research Center convened to discuss the future of healthcare
Sheffield, UK, October 2 2025 – Rinri Therapeutics, a world leading company focused on transforming sensorineural hearing loss (SNHL) with regenerative cell therapy, has been awarded the Grand Prize of $1m in research funding at the 2nd Annual Life Sciences Innovation Summit in Saudi Arabia, convened by J.P. Morgan Asset Management and King Abdullah International Medical Research Center. Selected from a cohort of leading global biotech innovators, the Prize recognises the potential of the company’s lead first-in-class regenerative cell therapy Rincell-1 to restore hearing.
The event brought together innovators, investors and industry leaders to explore the latest advancements and trends shaping the future of healthcare in Saudi Arabia.
Dr Simon Chandler, CEO of Rinri Therapeutics, said ‘This Grand Prize recognises the importance of advancing innovative and impactful therapeutics such as Rincell-1, our lead regenerative cell therapy for hearing loss, which is on the verge of a Phase I trial. We are delighted to be awarded this collaborative funding to accelerate development of our therapies for patients who urgently need them. Thanks are due to J.P. Morgan Asset Management and King Abdullah International Medical Research Center for organising such an insightful conference.’
–ENDS–
For more information contact:
Dr Simon Chandler, CEO enquiries@rinri-therapeutics.com
About Rinri Therapeutics
Rinri Therapeutics is focused on transforming sensorineural hearing loss (SNHL) with regenerative cell therapy, providing new therapeutic options for the treatment of this major global unmet medical need. It is developing first-in-class allogenic cell therapy products to treat hearing loss using its proprietary Otic Sensory Progenitor REgenerative therapY (OSPREY™) platform.
There are currently no approved therapeutics for the estimated more than 7m people living with neural hearing loss globally, giving Rinri Therapeutics’ cell therapies a multi-billion dollar sales potential. The company is headquartered in Sheffield, UK, and backed by UCB Ventures, Boehringer Ingelheim Venture Fund and Pioneer Group. For more information, please visit https://www.rinri-therapeutics.com/ or follow us on LinkedIn.
